These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24525598)

  • 1. Effect of icodextrin on heart rate variability in diabetic patients on peritoneal dialysis.
    Orihuela O; de Jesús Ventura M; Ávila-Díaz M; Cisneros A; Vicenté-Martínez M; Furlong MD; García-González Z; Villanueva D; Alcántara G; Lindholm B; García-López E; Villanueva C; Paniagua R
    Perit Dial Int; 2014; 34(1):57-63. PubMed ID: 24525598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Echocardiographic, electrocardiographic and blood pressure changes induced by icodextrin solution in diabetic patients on peritoneal dialysis.
    Paniagua R; Orihuela O; Ventura MD; Avila-Díaz M; Cisneros A; Vicenté-Martínez M; Furlong MD; García-González Z; Villanueva D; Prado-Uribe MD; Alcántara G; Amato D
    Kidney Int Suppl; 2008 Apr; (108):S125-30. PubMed ID: 18379535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients.
    Paniagua R; Ventura MD; Avila-Díaz M; Cisneros A; Vicenté-Martínez M; Furlong MD; García-González Z; Villanueva D; Orihuela O; Prado-Uribe MD; Alcántara G; Amato D
    Perit Dial Int; 2009; 29(4):422-32. PubMed ID: 19602608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial.
    Takatori Y; Akagi S; Sugiyama H; Inoue J; Kojo S; Morinaga H; Nakao K; Wada J; Makino H
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1337-44. PubMed ID: 21493740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Icodextrin metabolism and alpha-amylase activity in nonuremic rats undergoing chronic peritoneal dialysis.
    García-López E; Pawlaczyk K; Anderstam B; Qureshi AR; Kuzlan-Pawlaczyk M; Heimbürger O; Werynski A; Lindholm B
    Perit Dial Int; 2007; 27(4):415-23. PubMed ID: 17602150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Icodextrin reduces insulin resistance in non-diabetic patients undergoing automated peritoneal dialysis: results of a randomized controlled trial (STARCH).
    de Moraes TP; Andreoli MC; Canziani ME; da Silva DR; Caramori JC; Ponce D; Cassi HV; de Andrade Bastos K; Rio DR; Pinto SW; Filho SR; de Campos LG; Olandoski M; Divino-Filho JC; Pecoits-Filho R
    Nephrol Dial Transplant; 2015 Nov; 30(11):1905-11. PubMed ID: 26063787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid.
    Lin A; Qian J; Li X; Yu X; Liu W; Sun Y; Chen N; Mei C;
    Clin J Am Soc Nephrol; 2009 Nov; 4(11):1799-804. PubMed ID: 19808224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between ultrafiltrate volume with icodextrin and peritoneal transport pattern according to the peritoneal equilibration test.
    Araújo Teixeira MR; Pecoits-Filho RF; Romão Junior JE; Sabbaga E; Marcondes MM; Abensur H
    Perit Dial Int; 2002; 22(2):229-33. PubMed ID: 11990408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Icodextrin Versus Glucose Solutions for the Once-Daily Long Dwell in Peritoneal Dialysis: An Enriched Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Goossen K; Becker M; Marshall MR; Bühn S; Breuing J; Firanek CA; Hess S; Nariai H; Sloand JA; Yao Q; Chang TI; Chen J; Paniagua R; Takatori Y; Wada J; Pieper D
    Am J Kidney Dis; 2020 Jun; 75(6):830-846. PubMed ID: 32033860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of high and low molecular weight molecules of icodextrin in plasma and dialysate, using gel filtration chromatography, in peritoneal dialysis patients.
    García-López E; Anderstam B; Heimbürger O; Amici G; Werynski A; Lindholm B
    Perit Dial Int; 2005; 25(2):181-91. PubMed ID: 15796147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Icodextrin: a review of its use in peritoneal dialysis.
    Frampton JE; Plosker GL
    Drugs; 2003; 63(19):2079-105. PubMed ID: 12962523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo.
    Bajo MA; Selgas R; Castro MA; del Peso G; Diaz C; Sánchez-Tomero JA; Fernandez de Castro M; Alvarez V; Corbí A
    Perit Dial Int; 2000; 20(6):742-7. PubMed ID: 11216569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of peritoneal equilibrium test with icodextrin and 2.5% glucose dialysis solutions.
    Hwang JC; Wang HY; Wang CT; Chen HC
    J Nephrol; 2006; 19(6):758-63. PubMed ID: 17173249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peritoneal defense using icodextrin or glucose for daytime dwell in CCPD patients.
    Posthuma N; ter Wee P; Donker AJ; Dekker HA; Oe PL; Verbrugh HA
    Perit Dial Int; 1999; 19(4):334-42. PubMed ID: 10507814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of a continuous ambulatory peritoneal dialysis (CAPD) technique with one icodextrin-containing and two biocompatible glucose-containing dialysates for preservation of residual renal function and biocompatibility in incident CAPD patients.
    Yoon HE; Chang YK; Shin SJ; Choi BS; Kim BS; Park CW; Song HC; Yoon SA; Jin DC; Kim YS
    J Korean Med Sci; 2014 Sep; 29(9):1217-25. PubMed ID: 25246739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized clinical trial to evaluate the effects of icodextrin on left ventricular mass index in peritoneal dialysis.
    Cordeiro L; Ishikawa WY; Andreoli MCC; Canziani MEF; Araujo LKRP; Pereira BJ; Abensur H; Moysés RMA; Elias RM
    Sci Rep; 2022 Sep; 12(1):15776. PubMed ID: 36138087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peritoneal accumulation of advanced glycosylation end-products in diabetic rats on dialysis with icodextrin.
    Lee JH; Reddy DK; Saran R; Moore HL; Twardowski ZJ; Nolph KD; Khanna R
    Perit Dial Int; 2000; 20 Suppl 5():S39-47. PubMed ID: 11229611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of icodextrin and glucose-containing solutions on insulin resistance in CAPD patients.
    Gürsu EM; Ozdemir A; Yalinbas B; Gürsu RU; Canbakan M; Güven B; Atasoyu EM; Keskin AT; Elçi A; Baru Y
    Clin Nephrol; 2006 Oct; 66(4):263-8. PubMed ID: 17063993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of icodextrin-based solutions on peritoneal transport in rats undergoing chronic peritoneal dialysis.
    Pawlaczyk K; Garcia-Lopez E; Kuzlan-Pawlaczyk M; Heimbürger O; Bergström J; Breborowicz A; Lindholm B
    Perit Dial Int; 2001; 21 Suppl 3():S359-61. PubMed ID: 11887855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteome profile of peritoneal effluents in children on glucose- or icodextrin-based peritoneal dialysis.
    Bruschi M; Candiano G; Santucci L; Petretto A; Mangraviti S; Canepa A; Perri K; Ghiggeri GM; Verrina E
    Nephrol Dial Transplant; 2011 Jan; 26(1):308-16. PubMed ID: 20584736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.